Mark Rolfe’s Post

The video Mark mentions below is great to learn more about protein degradation!

Thanks again all for attending the event! Please keep eyes on the further communication for the next webinar event "Mastering Non-Clinical Challenges in Drug Development: A Roadmap to Success"

On Rare Disease Day, we send our congratulations to the PharmAust team on the recently released top line results from their Phase 1 MEND study, assessing monepantel as a potential therapy for Motor Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS). This work has found that "monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio®", while "preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy endpoint, ALSFRS-R". More detail on these results can be found in the below presentation, delivered by PharmAust CEO, Dr Michael Thurn. Alithia Life Sciences is extremely proud to be associated with this groundbreaking research and we look forward to supporting future phases of this study when they commence in the second half of 2024. #rarediseaseday #raredisease #rarediseases #motorneuronedisease #mnd #als #clinicalresearch #clinicaltrial #medicalresearch #scientificresearch #medicaltreatment

Remember to put our next webinar in your diary! All details below ⬇

Meet Tina Marriott (Larson), our President and COO, in the latest of our #Recursionaut Series. 🌟 With an extensive career in biopharma spanning Genentech, Roche, and Achaogen, Tina now plays a critical role in merging science and technology here at Recursion to advance the future of medicine. Hear more from Tina about how new technologies and tools are transforming how we approach treating serious diseases. Watch ⬇️ to learn more. #Biotechnology #Engineering #Leadership #TechBio #WomenInSTEM #RecursionPharma #drugdiscovery

Check out this spotlight on our Discovery and Preclinical practice area. A quick video highlighting our practice area leader, Melissa Acevedo, and some recently completed searches. Get in touch with Melissa for anything Discovery and Preclinical: [email protected] #discovery #preclinical #biotechcareers #prestigescientific

**Please note that we have had to postpone this webinar due to external events, we will announce the new date shortly, stay tuned!** Join us for a discussion with the authors of the recently published article ‘Making Good Decisions in Early Drug Discovery’ (Drug Discovery Today June 2024). The conversation will focus on the critical elements of Decision Framing, which are key to enabling collaborative conversations and alignment with early drug discovery teams and the development of a clear decision roadmap. The approach was developed to address the challenges of decision making in drug discovery research in the face of uncertainty. The concept and tools associated with Decision Quality provide a helpful frame for team-based strategy development, scientific conversation and qualitative evaluation of plan options. During this webinar, we will discuss and answer the following questions: ✔ How is Decision Quality used to support early drug discovery? ✔ Which Decision Framing tools facilitate the development of alternative strategies and the Decision Roadmap? Registration Link: https://lnkd.in/gbQzdb9w #DecisionMaking #UncertaintyAnalysis #OnlineCourse #ProfessionalDevelopment #DecisionScience #DecisionQuality

Targeted Protein Degradation (TPD) has the potential to reshape the expectations of what is possible for many types of diseases by unlocking therapeutic targets previously deemed undruggable.     I believe it critical that we come together as an industry to share ideas and best practices to help accelerate the delivery of safe and effective protein degraders. That is why I was delighted to attend the 6th Annual TPD Summit in Boston, MA, to connect with other industry leaders and share invaluable insights. The conference reaffirmed how rapidly this field is advancing as a promising new modality, with an increasing number of clinical trials and developers focused on TPD. It was a privilege to share the progress @AstellasPharma is making in advancing a novel KRAS degrader with exciting first-in-class potential and discussing the speed with which we are advancing this program.     TPD is a promising technology that may bring a new era to the field of synthetic drug development. I am committed to leveraging our collective knowledge and collaborating with expert partners as we work to advance this exciting technology and create VALUE for patients around the globe.    #ScienceFirstForPatients #ChangingTomorrow #TargetedProteinDegradation 

Today BenevolentAI announces an update on our business priorities: 👉 We will focus on our drug discovery collaboration and proprietary pipeline revenue-generating pillars, following recent successes in both these areas, such as the recent Phase 1a data readout for our lead asset BEN-8744 for the treatment of ulcerative colitis 👉 Work on the Knowledge Exploration Tools will end, with proposed headcount reductions, meaning we can increase cash runway to late Q3 2025 👉 Importantly, key skills, experience and capabilities have been retained and these reductions do not diminish the Company’s ability to execute on existing, or sign new, collaborations and continue to develop its core pipeline programmes 💬 Our CEO Joerg Moeller: “I believe that focusing our organisation on furthering our drug discovery collaborations and progressing our proprietary pipeline is the best way of delivering value creation for our shareholders and delivering innovative medicines to patients suffering from very serious medical conditions”. You can read more here https://lnkd.in/eJ9pDHfN

🌟 NEWS: We have launched the clinical white paper! 🚀 In drug development, one of the most critical phases is the transition from preclinical stages to human trials. This involves moving from lab and animal studies to testing the drug's safety, dosage, and initial efficacy in humans. Professional planning and meticulous implementation at this stage are essential. Effective management streamlines subsequent clinical phases minimizes risks, addresses regulatory hurdles, and optimizes resources, thereby increasing the chances of success. This white paper focuses on three major factors that are essential for managing a smooth transition from preclinical to clinical research. The goal is to commence the clinical development program on time and ensure it is adequately designed to meet all planning targets. Check out our newly launched white paper: https://lnkd.in/e7CK3en8 and connect with our author, Wolfgang Timmer, if you have any questions or would like to discuss your project with us! #NUVISAN #preclinical #clinicaltrial #FIH